An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

TPOXX®

Drug Information Related Patent
Hold Company
SIGA TECHNOLOGIES
Learn More
Dosage and Administration
CAPSULE;ORAL
Specification
200MG
Indication
TPOXX® is indicated for the treatment of human smallpox disease caused by the variola virus in adult and pediatric patients weighing at least 3 kg.
Use
Instructions for Use
API
TECOVIRIMAT
API Structure
We Supply
TECOVIRIMAT
Note:

In-house Standard
Facility GMP
Product GMP
CDE/DMF/ASMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
77371682031/9/4
80395042027/7/23
81246432024/6/18
85305092024/6/18
88027142024/6/18
93394662031/3/23
API Patent
Patent NoExpiration Date
81246432024/6/18
85305092024/6/18
88027142024/6/18

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top